KalVista Pharmaceuticals Inc Stock News

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev

Janus Henderson Group PLC raised its position in Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 857.0% during the first quarter, according to the company in its most recent disclosure with the Securiti

In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL – Research Report),

In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),

Upgrades * Berenberg changed the rating for Mondelez International Inc (NASDAQ: MDLZ) from Hold to Buy. For the first quarter, Mondelez International had an EPS of $0.69, compared to year-ago quarte

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on KalVista Pharmaceuticals

After Mizuho Securities and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy,

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d

10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M

Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema

10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M

Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc

Acadian Asset Management LLC lifted its holdings in Haemonetics Co. (NYSE:HAE) by 9.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)

The